

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time	Wednesday 19 th May 2021, 1pm
Venue	WEBEX
Chair	Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician, HUTH
Quorate: Yes / No	Yes

Miss J Morgan, Senior Principal Pharmacist, HUTH
Dr B Ali, GP Prescribing Lead, ER CCG
Mrs E Baggaley, Head of Medicines Service, CHCP
Mr K McCorry, Senior Pharmacist, NECS
Dr B Eyo Consultant Psychiatrist in Addictions, Renew
Mrs C Hayward, Pharmacist, LPC
Prof A Morice, Professor of Respiratory Medicine, HUTH
Dr W Chong, Chief Pharmacist, HFTH
Mr A Ramirez, Deputy Chief Pharmacist, HUTH
Mr D Onyeagor, Pharmacist, Spire

Apologies	Mr P Davis, Strategic Lead Primary Care, Hull, CCG Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HUTH Mr P McGorry, Pharmacist, LPC
------------------	--

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.05.01	Apologies	As above				March 21
2021.05.02	Declarations of Interest	None				March 21
2021.05.05	Minutes of the Previous Meeting	Accepted as a true record				March 21
2021.05.04	Matters Arising & Action Tracker	<p>RMOC JM to update on progress of heparinised saline guideline, trust guideline being reviewed JM in contact with team. Remove from tracker bring back if new guideline written</p> <p>Correspondence Received Rheumatology to prepare pathway with rituximab without MTX, JM told the committee this pathway is going to be very different in layout from current pathway and once written will need approval by commissioners therefore committee agreed to move completion date to Nov 2021</p> <p>Humber CCG Evidence Based Interventions KMc to discuss wording of document with commissioners, this has now been moved to July meeting</p> <p>Action Tracker RS to discuss SCF with GCP and feedback</p> <p>RMOC Buprenorphine LA Injection still waiting for commissioners to agree to funding so service not started yet</p> <p>PG/SCF KMc has taken Ketorolac and Glycopyrronium guidelines to CCGs and they have both been approved by Hull and ER NEW ACTION: WH to add to website</p>	<p>Remove from tracker</p> <p>Change completion date on tracker to Nov 21</p> <p>Leave on tracker for discussion in July</p> <p>RS not present to discuss</p> <p>Feedback next time</p> <p>Action complete</p> <p>WH to add to web</p>	<p>Leave on tracker</p> <p>Leave on tracker</p> <p>Leave on tracker</p>	<p>JM</p> <p>JM</p> <p>KMc</p> <p>RS</p> <p>WC</p> <p>KMc</p> <p>WH</p>	<p>May 21</p> <p>Nov 21</p> <p>Nov 20</p> <p>Jan 21</p> <p>March 21</p> <p>May 21</p> <p>July 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>NatPSA Emergency Steroid Card DC has discussed with Mr Vize. HUTH have now written and approved an internal guideline, the committee requested JM use trust guidance to write separate guidance for HERPC with a view to adding to the website. NEW ACTION: JM to prepare guideline</p>	Action complete		JM	May 21
		<p>HUTH Nutrition Pathway Update RG circulated the presentation to the group</p>	JM to prepare ESC guideline for HERPC		JM	July 21
		<p>HUTH Nutrition Pathway Update RG sent information to CH on how to obtain free samples</p>	Action complete		RS	May 21
		<p>HUTH Nutrition Pathway Update RG sent information to CH on how to obtain free samples</p>	Action complete		RS	May 21
		<p>HUTH Nutrition Pathway Update RG emailed EB information for carehomes</p>	Action complete		RS	May 21
		<p>Traffic Light Status WH has updated the red list</p>	Action complete		WH	May 21
		<p>Traffic Light Status AM has put together the airway committee to review COPD and asthma pathways the first meeting is to take place next week</p>	Action complete		AM	May 21
		<p>Traffic Light Status JM will chase dermatology to update their biological pathway.</p>	JM to chase		JM	May 21
		<p>The Rheumatology one is much larger and therefore needs a longer period to prepare</p>				Jan 22
		<p>Feedback from Commissioning Groups JM has amended the Modafanil SCF and added to the website</p>	Action complete		JM	May 21
		<p>PG/SCF WH has updated the website</p>	Action complete		WH	May 21
		<p>PG/SCF JM has amended the SCF for both MAOIs and they are now on the HERPC website</p>	Action complete		JM	May 21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.05.05	Traffic Light Status	<p>Pemigatanib for cholangiocarcinoma available via EAMS scheme no further work required will be classified as RED.</p> <p>Dapagliflozin already on formulary for T2DM new indication of chronic heart failure TA679 Chronic Heart Failure guideline to be updated. Dapagliflozin will remain blue for T2DM and RED for heart failure.</p> <p>Erenumab TA682 Chronic and Episodic migraine guidance has been updated and is on agenda for discussion, classification agreed as RED</p>	<p>WH to update red list</p> <p>JM to update HF guideline</p> <p>WH to update red list</p>		<p>WH</p> <p>JM</p> <p>WH</p>	<p>July 21</p> <p>July 21</p> <p>July 21</p>
2021.05.06	Feedback From Commissioning Groups	<p>Both Ketorolac and Glycopyrronium guidelines approved by both CCGs, and all decisions made at February and March HUTH D&T have been approved.</p> <p>The Biquelle rebate has been renewed by Hull CCG</p> <p>The guidance for acute relapsing remitting MS has been queried by ER CCG and KMc and JM are working together to deal with query and gain CCG approval.</p>	<p>WH to add to website</p> <p>JM to discuss with microbiology then KMc</p>		<p>WH</p> <p>JM/KMc</p>	<p>July 21</p> <p>July 21</p>
2021.05.07	Prescribing guidelines, shared care frameworks for approval	<p>HERPC guidelines for discussion</p> <p>NEW</p> <ul style="list-style-type: none"> TA679 Dapagliflozin for heart failure – already on formulary as green for T2DM but will need to be added as Blue guideline led for heart failure JM has reviewed guideline and is awaiting comments from Prof Clark to proceed with update. ONS Pathways HUTH have approved two new ONS pathways for patients admitted to HUTH, SR said it must be made very clear on patients IDL if a review is required. KMc requested they both be sent to the Hull and ER pathway review group and JM said she would be happy to attend with Ruth the dietitian JIC Leaflet Ditch the Dipstick New guidance recommends treating patients who present with UTI symptoms has opposed to treating because of urinary dipstick result which are not always accurate. The committee requested a link to the HERPC antibiotic guideline be added. <p>UPDATES</p> <ul style="list-style-type: none"> Guideline – Rifaxamin for Hepatic Encephalopathy - required review but document remains the same 	<p>JM to update HF guideline</p> <p>KMc to invite JM and RG to pathway committee to discuss</p> <p>JM to amend and add to website</p> <p>Approved</p>		<p>JM</p> <p>KMc</p> <p>JM</p> <p>WH</p>	<p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<ul style="list-style-type: none"> • Guideline – Gonadorelin Analogues – updated to remove Ulipristal from guideline, JM to remove reference to endometrial ablation. • SCF Tamoxifen for chemo prevention of familial breast cancer • SCF Raloxifene for chemo prevention of familial breast cancer • SCF Anastrozole for chemo prevention of familial breast cancer <p>All three updated to include reference to unlicensed use of licensed product, contact details have been updated and all references to fax machines removed</p> <ul style="list-style-type: none"> • SCF Degarelix for prostate cancer JM has added the request for increased monitoring of diabetic patients who receive degarelix therapy the committee ask if JM would discuss with Mr Simms and Mr Smith the addition of Hb1c monitoring. JM has also update the adverse effects section to include more commonly occurring side effects. <ul style="list-style-type: none"> • Glaucoma Guideline Updated with no new additions but brand names have been removed where generic products are now available. • Ocular Lubricant Guideline Updated with no new additions but brand names have been removed where generic products are now available • SCF Azathioprine and Mercaptopurine in Inflammatory Bowel Disease and Auto Immune Hepatitis • Medicines Management Tool for Antipsychotics HFTH have updated by reformatting and including links instead of embedded documents. Lurasidone has now been included and the monitoring forms have been updated. WC to send copies of the forms to JM for addition to the website • Migraine and Cluster Headaches Updated to include Erenumab <p>EXTENDING REVIEW DATES</p> <ul style="list-style-type: none"> • DMARDS – JM asked if it would be possible to extend the review dates of the DMARD SCF due the ongoing work by rheumatology to update their pathways, the committee agreed to extend review dates to Jan 22 by which time a lot of the RMOC documents would be published. 	<p>Approved</p> <p>Approved Approved Approved</p> <p>JM to discuss with Mr Simms and Mr Smith</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p> <p>WC to forward monitoring forms to JM to add to website</p> <p>Approved</p> <p>Agreed to extend review dates until Jan 22</p>	<p>documents to the website</p> <p>Website documents to have review date extended</p>	<p>JM</p> <p>WC</p> <p>WH</p>	<p>July 21</p> <p>July 21</p> <p>July 21</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.05.08	Joint Humber APC	JM has been working alongside Karen Hiley on the merger of the four APCs for North Lincs North East Lincs Hull and East Riding, a paper has been written and JM will circulate post meeting. This is going to be an intensive piece of work bringing together the formularies, guidelines and SCF across the four areas the aim is to have the joint APC up and running by the ICS go live date of April 2022	Noted	No further action		May 21
2021.05.09	MHRA DSU	<ul style="list-style-type: none"> • March 2021 Bendamustine (Levact) : increased risk of non melanoma skin cancer and progressive multifocal encephalopathy Covid 19: Vaccines and Medicines Updates for March 2021 <ul style="list-style-type: none"> • April 2021 Polyethylene Glycol (PEG) laxatives and starch based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration HUTH guidance only recommends use of guar based thickeners Covid 19 Vaccines:updates for April 21	Noted	No further action		May 21
2021.05.10	Regional Medicines Optimisation Committee	Buprenorphine Long Acting Injection Guidance – this has now been ratified Shared Care Guidance - this has now been ratified by NHSE Shared Care Workplan & Shared Care Consultation HUTH are working on electronic SCF which can be sent straight to EMIS and systm1 however this would still require GPs to print sign and post back to the specialists. HUTH would like to use the RMOC recommended checklists instead of front sheet to enable electronic submission to GPs. JM is looking at reformatting template so that tables can be included and is clearer following GP feedback. JM said whilst working on this we must also take into consideration the APC merger HUTH/HFTH have access to Lorenzo and how with NLAG PAS system works. The committee also felt that the LMC & LPC should be involved in these discussions going forward.	Noted	No further action		May 21
2021.05.11	Correspondence Received	Denosumab SCF adoption in primary care Dr Aye and Dr Saharia at HUTH have expressed a concern that many GPs will not adopt the Denosumab SCF and ask the committee why they think this is, the committee felt that the SCF was very “wordy” and that the complexity of the document was the main barrier to adoption.	JM to feedback committees comments		JM	July 21

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2021.05.12	Primary Care Rebate Scheme	Biquelle rebate has been renewed by Hull CCG.	Noted	No further action		May 21
2021.05.13	Additional Minutes for Information	a) MMIG (March, April) b) HEY D&T (March) c) HTFT DTC (January) d) CHCP e) Formulary Sub Group f) Hull CC Planning & Commissioning (none this month)	Noted	No further action		May 21
2021.05.14	A.O.B	<p>JM asked if GP practices had been able to procure cefotaxime injection, which is recommended as an alternative for patients with a penicillin allergy to benzylpenicillin in the initial treatment of meningitis. Some wholesalers will supply to hospitals only. JM has discussed with the ID dept who have suggested ceftriaxone as an alternative if required. Ceftriaxone and Cefotaxime are both red on joint formulary but will need to be altered to blue to enable this change.</p> <p>SR said he had had a few patients in his practice discharged from other trusts whereby they had been initiated on warfarin but not provided with a yellow book. The committee agreed this should be further discussed at the next MMIG meeting.</p>	<p>JM to look into adding ceftriaxone to guideline as an option.</p> <p>WH to alter status to blue on joint formulary</p> <p>JM to send SR a copy of the trust anticoagulation check sheet</p> <p>WH to add to MMIG agenda</p>		<p>JM</p> <p>WH</p> <p>JM</p> <p>WH</p>	<p>July 21</p> <p>July 21</p> <p>July 21</p> <p>July 21</p>
	Date and Time of Next Meeting	Wednesday 21st July 2021, 1pm, WEBEX				